91 related articles for article (PubMed ID: 15780728)
1. A strong CD8+ T cell response is elicited using the synthetic polypeptide from the C-terminus of the circumsporozoite protein of Plasmodium berghei together with the adjuvant QS-21: quantitative and phenotypic comparison with the vaccine model of irradiated sporozoites.
Meraldi V; Romero JF; Kensil C; Corradin G
Vaccine; 2005 Apr; 23(21):2801-12. PubMed ID: 15780728
[TBL] [Abstract][Full Text] [Related]
2. Immunization with radiation-attenuated Plasmodium berghei sporozoites induces liver cCD8alpha+DC that activate CD8+T cells against liver-stage malaria.
Jobe O; Donofrio G; Sun G; Liepinsh D; Schwenk R; Krzych U
PLoS One; 2009; 4(4):e5075. PubMed ID: 19347042
[TBL] [Abstract][Full Text] [Related]
3. Discriminating Protective from Nonprotective Plasmodium-Specific CD8+ T Cell Responses.
Doll KL; Pewe LL; Kurup SP; Harty JT
J Immunol; 2016 May; 196(10):4253-62. PubMed ID: 27084099
[TBL] [Abstract][Full Text] [Related]
4. Irradiated sporozoite vaccination induces sex-specific immune responses and protection against malaria in mice.
Vom Steeg LG; Flores-Garcia Y; Zavala F; Klein SL
Vaccine; 2019 Jul; 37(32):4468-4476. PubMed ID: 31262583
[TBL] [Abstract][Full Text] [Related]
5. Immunogenicity and protective efficacy of a recombinant yellow fever vaccine against the murine malarial parasite Plasmodium yoelii.
Stoyanov CT; Boscardin SB; Deroubaix S; Barba-Spaeth G; Franco D; Nussenzweig RS; Nussenzweig M; Rice CM
Vaccine; 2010 Jun; 28(29):4644-52. PubMed ID: 20451637
[TBL] [Abstract][Full Text] [Related]
6. Variable long-term protection by radiation-, chemo-, and genetically-attenuated Plasmodium berghei sporozoite vaccines.
Moita D; Nunes-Cabaço H; Rôla C; Franke-Fayard B; Janse CJ; Mendes AM; Prudêncio M
Vaccine; 2023 Dec; 41(51):7618-7625. PubMed ID: 38007342
[TBL] [Abstract][Full Text] [Related]
7. Genetically attenuated, P36p-deficient malarial sporozoites induce protective immunity and apoptosis of infected liver cells.
van Dijk MR; Douradinha B; Franke-Fayard B; Heussler V; van Dooren MW; van Schaijk B; van Gemert GJ; Sauerwein RW; Mota MM; Waters AP; Janse CJ
Proc Natl Acad Sci U S A; 2005 Aug; 102(34):12194-9. PubMed ID: 16103357
[TBL] [Abstract][Full Text] [Related]
8. OX40 Stimulation Enhances Protective Immune Responses Induced After Vaccination With Attenuated Malaria Parasites.
Othman AS; Franke-Fayard BM; Imai T; van der Gracht ETI; Redeker A; Salman AM; Marin-Mogollon C; Ramesar J; Chevalley-Maurel S; Janse CJ; Arens R; Khan SM
Front Cell Infect Microbiol; 2018; 8():247. PubMed ID: 30073152
[TBL] [Abstract][Full Text] [Related]
9. A nonintegrative lentiviral vector-based vaccine provides long-term sterile protection against malaria.
Coutant F; Sanchez David RY; Félix T; Boulay A; Caleechurn L; Souque P; Thouvenot C; Bourgouin C; Beignon AS; Charneau P
PLoS One; 2012; 7(11):e48644. PubMed ID: 23133649
[TBL] [Abstract][Full Text] [Related]
10. Exacerbation of autoimmune neuro-inflammation in mice cured from blood-stage Plasmodium berghei infection.
Thomé R; Bombeiro AL; Issayama LK; Rapôso C; Lopes SC; da Costa TA; Di Gangi R; Ferreira IT; Longhini AL; Oliveira AL; da Cruz Höfling MA; Costa FT; Verinaud L
PLoS One; 2014; 9(10):e110739. PubMed ID: 25329161
[TBL] [Abstract][Full Text] [Related]
11. Preliminary studies on the immunogenicity of a prime-and-trap malaria vaccine in nonhuman primates.
Shears MJ; Watson FN; Stone BC; Cruz Talavera I; Parthiban C; Matsubara J; Kc N; Sim BKL; Hoffman SL; Murphy SC
Vaccine; 2023 Aug; 41(38):5494-5498. PubMed ID: 37563050
[TBL] [Abstract][Full Text] [Related]
12. Updated insights into the mechanism of action and clinical profile of the immunoadjuvant QS-21: A review.
Lacaille-Dubois MA
Phytomedicine; 2019 Jul; 60():152905. PubMed ID: 31182297
[TBL] [Abstract][Full Text] [Related]
13. Analysis of CD8 T-cell response by IFNgamma ELISPOT and H-2L(d)/pRL1a tetramer assays in pRL1a multiple antigen peptide-immunized and RL male 1-bearing BALB/c and (BALB/c x C57BL/6) F(1) mice.
Takada I; Noguchi Y; Kenjo A; Wada H; Uenaka A; Fujita T; Inoue H; Nakayama E
Cancer Sci; 2004 Mar; 95(3):254-9. PubMed ID: 15016326
[TBL] [Abstract][Full Text] [Related]
14. Low immunogenicity of malaria pre-erythrocytic stages can be overcome by vaccination.
Müller K; Gibbins MP; Roberts M; Reyes-Sandoval A; Hill AVS; Draper SJ; Matuschewski K; Silvie O; Hafalla JCR
EMBO Mol Med; 2021 Apr; 13(4):e13390. PubMed ID: 33709544
[TBL] [Abstract][Full Text] [Related]
15. Ageing of Plasmodium falciparum malaria sporozoites alters their motility, infectivity and reduces immune activation in vitro.
van Schuijlenburg R; Azargoshasb S; de Korne CM; Sijtsma JC; Bezemer S; van der Ham AJ; Baalbergen E; Geurten F; de Bes-Roeleveld LM; Chevalley-Maurel SC; van Oosterom MN; van Leeuwen FWB; Franke-Fayard B; Roestenberg M
Malar J; 2024 Apr; 23(1):111. PubMed ID: 38641838
[TBL] [Abstract][Full Text] [Related]
16. A potent adjuvant effect of a CD1d-binding NKT cell ligand in human immune system mice.
Li X; Huang J; Kaneko I; Zhang M; Iwanaga S; Yuda M; Tsuji M
Expert Rev Vaccines; 2017 Jan; 16(1):73-80. PubMed ID: 27801602
[TBL] [Abstract][Full Text] [Related]
17. A Novel Protozoa Parasite-Derived Protein Adjuvant Is Effective in Immunization with Cancer Cells to Activate the Cancer-Specific Protective Immunity and Inhibit the Cancer Growth in a Murine Model of Colorectal Cancer.
Mani R; Martin CG; Balu KE; Wang Q; Rychahou P; Izumi T; Evers BM; Suzuki Y
Cells; 2024 Jan; 13(2):. PubMed ID: 38247803
[TBL] [Abstract][Full Text] [Related]
18. Elicitation of T-cell-derived IFN-γ-dependent immunity by highly conserved Plasmodium ovale curtisi Duffy binding protein domain region II (PocDBP-RII).
Ren Z; Shi Q; Xu S; Xu J; Yin Y; Lin Z; Xu S; Ma X; Liu Y; Zhu G; He X; Lu J; Li Y; Zhang W; Liu J; Yang Y; Han ET; Cao J; Lu F
Parasit Vectors; 2023 Aug; 16(1):269. PubMed ID: 37553591
[TBL] [Abstract][Full Text] [Related]
19. Dynamics of the major histocompatibility complex class I processing and presentation pathway in the course of malaria parasite development in human hepatocytes: implications for vaccine development.
Ma J; Trop S; Baer S; Rakhmanaliev E; Arany Z; Dumoulin P; Zhang H; Romano J; Coppens I; Levitsky V; Levitskaya J
PLoS One; 2013; 8(9):e75321. PubMed ID: 24086507
[TBL] [Abstract][Full Text] [Related]
20. mRNA vaccine against malaria tailored for liver-resident memory T cells.
Ganley M; Holz LE; Minnell JJ; de Menezes MN; Burn OK; Poa KCY; Draper SL; English K; Chan STS; Anderson RJ; Compton BJ; Marshall AJ; Cozijnsen A; Chua YC; Ge Z; Farrand KJ; Mamum JC; Xu C; Cockburn IA; Yui K; Bertolino P; Gras S; Le Nours J; Rossjohn J; Fernandez-Ruiz D; McFadden GI; Ackerley DF; Painter GF; Hermans IF; Heath WR
Nat Immunol; 2023 Sep; 24(9):1487-1498. PubMed ID: 37474653
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
